BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...
Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key ...
The mRNA technology behind coronavirus vaccines is now being used to create bespoke vaccines for cancer patients.
Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an attractive alternative to ...
Vaccine hesitancy and higher rates of school vaccine exemptions increases the risk of outbreaks of preventable diseases, creating a significant health risk for vulnerable populations.
The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how to increase uptake.
ImmunoPrecise Antibodies has secured a collaboration with an undisclosed “leading biotech” to discover new antibody-drug ...
In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Exelixis (EXEL – Research Report). The ...
The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...
The National Institutes of Health is terminating dozens of studies examining why people are hesitant about vaccines and how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results